Arcutis Biotherapeutics Inc expected to post a loss of 86 cents a share - Earnings Preview

Arcutis Biotherapeutics

01/11/2023 11:02

* Arcutis Biotherapeutics Inc  ARQT.OQ   ARQT.O  is expected
to show a rise in quarterly revenue when it reports  results 
    * The Westlake Village California-based  company is expected
to
report  a 4,428.1% increase in revenue to $32.829 million from
$725 thousand a year ago, according to the mean estimate from 7
analysts, based on LSEG data. 
    * ​Refinitiv's mean analyst estimate for Arcutis
Biotherapeutics
Inc is for a loss of 86 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Arcutis
Biotherapeutics Inc is $33​, above​ its last closing price
of $2.25. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -1.25       -1.25      -1.16     Beat    7.2
 Mar. 31 2023  -1.26       -1.28      -1.31     Missed  -2
 Dec. 31 2022  -1.41       -1.42      -1.18     Beat    17.1​
 Sep. 30 2022  -1.70       -1.67      -1.89     Missed  -13.2
 ​​Jun.        -1.41       -1.43      -1.31     Beat    8.6
 30 2022                                                
 Mar. 31 2022  -1.51       -1.50      -1.27     Beat    15.4​
 Dec. 31 2021  -1.40       -1.49      -1.42     Beat    5
 Sep. 30 2021  -1.16       -1.15      -1.14     Beat    1
 This summary was machine generated November 1 at 11:01 GMT.  All
figures in US dollars  unless otherwise stated